ResMed Inc. RMD
Set alert
As of Nov 2, 10:55 AM ET
- YTD
- -5.27%
- 1 year
- -7.57%
- Open
- 231.27
- Prev close
- 229.94
- Mkt cap
- 32.11B
- Vol
- 325.23K
- Avg vol
- 1.35M
- EPS
- 10.98
- P/E
- 20.79
- Div yield
- 1.04%
More statistics
- Low
- 227.73
- High
- 233.29
- Forward P/E
- 17.34
- Beta
- 0.75
- Short ratio
- 10.34
- Inst. own
- 73.30%
- Dividend
- 2.64
- Ex-div date
- Aug 19, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 231.77
- 200-d avg
- 225.03
- 1y target
- 251.52
5D chart
Events in this range
- Oct 29, 2026Earnings: 2.91; estimate 2.69; surprise 8.18%
- Oct 30, 2026Rating: Keybanc · Overweight → Overweight
- Oct 30, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Oct 30, 2026Rating: RBC Capital · Outperform → Outperform
Signals (133)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 10:05 AM | 50 minutes ago |
| SMA: Bullish | Nov 2, 10:00 AM | 55 minutes ago |
| SMA: Bearish | Nov 2, 9:35 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 9:30 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 9:30 AM | 1 hour ago |
| MACD: Sell Signal | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 6 days ago |
News
6 hours ago fool.com
ResMed: 3 Key Takeaways for Long-Term Investors
ResMed reported that core constant currency revenue grew 7% in the first quarter. Patients on GLP-1 drugs are 11% more likely to start CPAP therapy.
-
2 days ago benzinga.com
Citigroup Maintains Neutral on ResMed, Raises Price Target to $270
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Neutral and raises the price target from $240 to $270.
-
2 days ago benzinga.com
RBC Capital Maintains Outperform on ResMed, Raises Price Target to $288
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.
-
2 days ago benzinga.com
Wells Fargo Maintains Equal-Weight on ResMed, Raises Price Target to $250
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.
3 days ago zacks.com
ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
-
3 days ago benzinga.com
Keybanc Maintains Overweight on ResMed, Raises Price Target to $277
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $267 to $277.
3 days ago zacks.com
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.
3 days ago marketbeat.com
What ResMed (RMD) Said on Its Q1 Earnings Call
ResMed NYSE: RMD reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks…
3 days ago seekingalpha.com
ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript
ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript
3 days ago zacks.com
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.67 per share. This compares to earnings of $2.55 per share a year ago.
3 days ago benzinga.com
ResMed Q1 2027 Earnings Call Transcript
ResMed (NYSE:RMD) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below.
3 days ago benzinga.com
ResMed Q1 2027 Earnings Call Transcript
ResMed (NYSE:RMD) reported first-quarter financial results on Thursday. The transcript from the company’s first-quarter earnings call has been provided below.This transcript is brought to you by…
-
3 days ago benzinga.com
ResMed Sees FY2027 Adj EPS $12.00-$12.25 vs $12.09 Est; Sees Sales $5.750B-$5.850B vs $5.814B Est
ResMed (NYSE:RMD) is looking for FY2027 Adj EPS of $12.00-$12.25 vs $12.09 analyst estimate. sees sales of $5.750 billion-$5.850 billion vs $5.814 billion analyst estimate.
-
3 days ago benzinga.com
ResMed Q1 Adj. EPS $2.91 Beats $2.67 Estimate, Sales $1.415B Beat $1.392B Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $2.91 per share which beat the analyst consensus estimate of $2.67 by 8.99 percent. This is a 14.12 percent increase over earnings of $2.55 per share…
3 days ago globenewswire.com
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
4 days ago zacks.com
Here's Why ResMed (RMD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
4 days ago benzinga.com
If You Invested $1000 In ResMed Stock 20 Years Ago, You Would Have This Much Today
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 3.82% on an annualized basis producing an average annual return of 12.81%. Currently, ResMed has a market capitalization of…
5 days ago zacks.com
Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the…
1 week ago zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
3 weeks ago benzinga.com
ResMed Q4 2026 Earnings Call Transcript
ResMed (NYSE:RMD) reported fourth-quarter financial results on Thursday. The transcript from the company's fourth-quarter earnings call has been provided below. Benzinga APIs provide real-time access…
3 weeks ago benzinga.com
Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%
Stocks fell and small caps slumped Wednesday as the 30-year Treasury yield hit 5.7%, a 24-year high, with Fed minutes and bond auctions ahead.
-
1 month ago benzinga.com
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262
RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.
-
2 months ago benzinga.com
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $255 to $267.
-
2 months ago benzinga.com
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230
Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.
-
2 months ago benzinga.com
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.
-
2 months ago benzinga.com
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225
Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.
-
2 months ago benzinga.com
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $225 to $215.
2 months ago benzinga.com
Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.
-
2 months ago benzinga.com
ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.89 by 2.08 percent. This is a 15.69 percent increase over earnings of $2.55 per share…
-
3 months ago benzinga.com
Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220
Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $235 to $220.
3 months ago benzinga.com
Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday
Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.
-
3 months ago benzinga.com
Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235
Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the price target from $270 to $235.
-
3 months ago benzinga.com
Jefferies Maintains Hold on ResMed, Lowers Price Target to $225
Jefferies analyst Matthew Taylor maintains ResMed (NYSE:RMD) with a Hold and lowers the price target from $240 to $225.
3 months ago benzinga.com
ResMed Analyst Backs Portfolio Reset
ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh near-term EPS dilution against long-term growth.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on ResMed, Lowers Price Target to $276
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $321 to $276.
-
3 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $225
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $227 to $225.
-
3 months ago benzinga.com
ResMed Says Deal Valued At $490M All-Cash, Expected To Close In Q1 FY2027
On July 7, 2026, ResMed Inc. (the "Company" or "Resmed") issued a press release announcing that on June 30, 2026 it entered into a definitive agreement to sell its MatrixCare business to Frazier
-
3 months ago benzinga.com
Resmed Strikes Agreement To Sell Its MatrixCare Operations To Frazier Healthcare Partners; Financial Terms Undisclosed
Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its…
-
4 months ago benzinga.com
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $266
Keybanc analyst Justin Patterson maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $290 to $266.
-
4 months ago benzinga.com
Here’s How Much You Would Have Made Owning ResMed Stock In The Last 20 Years
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 1.89% on an annualized basis producing an average annual return of 11.28%. Currently, ResMed has a market capitalization of…
4 months ago benzinga.com
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.
4 months ago benzinga.com
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, initiations. See opinions on EFC stock.
-
4 months ago benzinga.com
Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J B Hunt, Needham for Glaukos, B of A for CSX, Morgan Stanley for Charles River, and Bernstein for…
-
4 months ago benzinga.com
Morgan Stanley Downgrades ResMed to Equal-Weight, Lowers Price Target to $230
Morgan Stanley analyst David Bailey downgrades ResMed (NYSE:RMD) from Overweight to Equal-Weight and lowers the price target from $286 to $230.
-
5 months ago benzinga.com
ResMed Acquires Sleep-Related Wearables Developer Noctrix Health From Angelini Industries For $340M
Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company…
5 months ago benzinga.com
Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now And 1999 Is...'
Jim Cramer says investors are aggressively favoring AI stocks while heavily punishing companies that disappoint Wall Street.
-
6 months ago benzinga.com
RBC Capital Maintains Outperform on ResMed, Raises Price Target to $321
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $314 to $321.
-
6 months ago benzinga.com
Transcript: ResMed Q3 2026 Earnings Conference Call
Transcript: ResMed Q3 2026 Earnings Conference Call
-
6 months ago benzinga.com
Resmed Appoints Aaron Bloomer CFO, Succeeding Brett Sandercock
Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans…